US · Healthcare · Medical Instruments & Supplies
EPS came in at 0.29 against a street estimate of 0.30 — a miss of 3.3%.
Analysts rate Dentsply Sirona Inc a hold (4 buy, 12 hold, 1 sell out of 17) with an average price target of $12.40.
CAUTIOUS Q2 revenue $898M down 4.1%; adjusted EPS flat at $0.52 boosted by $44M tariff refunds. Management maintaining 2026 guidance despite ongoing turnaround headwinds. Expecting Q3 sequential decline, Q4 acceleration. Q2 2026 US implants lagging; EDS dealer inventory reduction in EMEA; APAC capex program showing positive uptake. EMEA seeing modest capex deferral from Middle East geopolitical uncertainty. Analysts pressed on turnaround credibility (team completeness, dealer impact timing) and underlying demand signals. Management emphasized long-term nature of clinical education ROI, distributor inventory as normalization not demand destruction, and Q4–2027 benefit realization. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 13.40% |
| Fuller & Thaler Asset Management Inc | 6.37% |
| Vanguard Portfolio Management, LLC | 5.91% |
| AQR Capital Management LLC | 5.25% |
| State Street Corp | 4.66% |
| Vanguard Capital Management, LLC | 4.54% |
| Lazard Asset Management LLC | 4.15% |
| Ariel Investments, LLC | 4.03% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 net sales were $836 million, down from $904 million in the third quarter of 2025. • Nine-month net sales were | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 net sales were $836 million, down 7.6% year over year and down 7.0% in constant currency. • GAAP gross margin was 52.9%, | 2026-11-05 |
| Material agreement · Q4 2026 HEADLINE NUMBERS • On October 8, 2026, DENTSPLY SIRONA obtained lender consent to amend its revolving credit facility and entered into amendments to | 2026-10-09 |
| Quarterly report · Q2 2026 DENTSPLY SIRONA INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Q2 2026 net sales: $898 million (down from $936 million in Q2 2025, -4%) • Six-month | 2026-08-06 |
| Current report · Q3 2026 DENTSPLY SIRONA INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company reported Q2 2026 financial results for quarter ended June 30, 2026 • Filing date: | 2026-08-06 |
| Board / officer change · Q2 2026 DENTSPLY SIRONA INC. (XRAY) - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company appointed John C. Fortson as Executive Vice President & Chief | 2026-06-11 |
| Shareholder vote results · Q2 2026 DENTSPLY SIRONA INC. (XRAY) - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held June 2, 2026 • Total votes cast (For + Against + A | 2026-06-04 |
| Quarterly report · Q1 2026 DENTSPLY SIRONA INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net sales: $880 million (Q1 2026) vs. $879 million (Q1 2025) — essentially flat year- | 2026-05-05 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.16 / share ex-date Dec 26, 2025 · pay Jan 9, 2026 | 2025-12-26 |
| Announcement | Date |
|---|---|
| Successfully entered into new non-exclusive distribution agreements for dental equipment DENTSPLY SIRONA announced it has signed new non-exclusive distribution agreements with Patterson for dental equipment distribution in the United States. This expands the company's market rea | 2026-01-14 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Dentsply Sirona Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.